All News
Consensus Against Interventional Injections for Chronic Spinal Pain
BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or inflammatory arthropathy.
Consensus on Bone Turnover Biomarkers in Osteoporosis
d
EurekAlert!
A new consensus paper, published by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), the International Osteoporosis Foundation (IOF), and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC),
Read Article
Patient Education handout on Carpal Tunnel Syndrome https://t.co/QwgZ8Jr7GQ https://t.co/wtg324nzlo
Links:
Dr. John Cush RheumNow ( View Tweet)

Diagnosing PMR is easy before Pred initiation; but after steroids NO SO. Before Pred, PMR Dx from non-PMR (median probabilities 7.8 vs 2.8) w/ 86% sensitivity/83% specificity. After Pred Dx probability of PMR dropped to 1.0 w/ sensitivity 3.5%; not much better w/ Pred D/C https://t.co/RRIYY6xleN
Dr. John Cush RheumNow ( View Tweet)

Barriers to current DMARD use from pts, discussed during routine visits were primarily related to side effects and concerns about the efficacy and long-term use. Continuous attention to these patients’ concerns are key to better treatment adherence https://t.co/J0kPR2CQyH https://t.co/D84t4dPdLO
Links:
Dr. John Cush RheumNow ( View Tweet)

Alberta Canada RA pt travel burden study showed median of 13 min to visit GPs & 34 min to visit rheums. Signif Rural/Urban disparities w/ 4-fold diff in GP travel & 8.7-fold diff in Rheum travel. Despite diff, travel time had little impact on health care utilization https://t.co/VqaDFJzfRs
Dr. John Cush RheumNow ( View Tweet)

Patient Education handout on Raynaud’s Phenomenon https://t.co/cm77mmmPSi https://t.co/GimQXHBdpp
Dr. John Cush RheumNow ( View Tweet)

“Medicine is a science of uncertainty and an art of probability.” - Sir William Osler https://t.co/SQH3JZcDfv
Dr. John Cush RheumNow ( View Tweet)

Targeting Obesity in Rheumatic Disease Patients
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.
https://t.co/OYtsbfJQ2e https://t.co/xEZI3mkY0q
Dr. John Cush RheumNow ( View Tweet)

Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis
A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/MaWx6AZ0JF
Dr. John Cush RheumNow ( View Tweet)

Increasing Prevalence of Osteoporosis
Research published in Osteoporosis International studied NHANES data showed increasing trends in osteoporosis in the United States of America.
https://t.co/KHWdMgjG0P https://t.co/lfXZA9F2JX
Dr. John Cush RheumNow ( View Tweet)

Autoimmune Disease Impact Report
Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/x3l9HIDul8
Dr. John Cush RheumNow ( View Tweet)

NP and PA Growth in the USA
Forbes has published a thoughtful perspective on the declining number of US physicians and the growth in the number of advanced practice providers or APPs in the US clinical workforce.
https://t.co/3Am8ZfEFo1 https://t.co/HeYfHc03Lu https://t.co/6H5wuf5RJ0
Dr. John Cush RheumNow ( View Tweet)

In 2021 the global rheumatoid arthritis market was valued at USD 22.77 billion and is expected to reach USD 33.30 billion by 2030. https://t.co/0vU6QP9JiG https://t.co/a8jXwk3KbK
Links:
Dr. John Cush RheumNow ( View Tweet)

Adrenal Dysfunction after Steroids in PMR and GCA Patients
JAMA has published a study of PMR and GCA patients who stopped glucocorticoid (GC) therapy and noted a low (1.2%) risk of GC-induced adrenal insufficiency after planned cessation.
https://t.co/zQSa8ex9na https://t.co/gkKxHFPuNe
Dr. John Cush RheumNow ( View Tweet)

Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/vWJrUN9C0H
Dr. John Cush RheumNow ( View Tweet)

MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm
Dr. John Cush RheumNow ( View Tweet)

If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/WO3gjxhVBw https://t.co/QdqtQMHcpL
Dr. John Cush RheumNow ( View Tweet)

Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m
Dr. John Cush RheumNow ( View Tweet)

Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb
Dr. John Cush RheumNow ( View Tweet)